{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T02:21:21Z","timestamp":1790130081155,"version":"4.0.1"},"reference-count":30,"publisher":"Instituto Nacional de Salud (Colombia)","issue":"Sp. 1","license":[{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100008347","name":"Bezmialem Vak\u0131f \u00dcniversitesi","doi-asserted-by":"publisher","award":["Decision No: 06.2015\/19"],"award-info":[{"award-number":["Decision No: 06.2015\/19"]}],"id":[{"id":"10.13039\/501100008347","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["revistabiomedica.org"],"crossmark-restriction":false},"short-container-title":["biomedica"],"abstract":"<jats:p>Introduction: More than half of all worldwide deaths and disabilities were caused by stroke. Large artery atherosclerosis is identified as a high etiological risk factor because it accounts for 20% of ischemic stroke.Objectives: To identify the significance of TRAIL and adropin release and the relative changes related to S100B levels, as well as the relationship between these biomarkers and the final infarct core, the clinical outcome, and the presence of large artery atherosclerosis in acute stroke patients.Materials and methods: Over a one-year period, demographic, clinical, and neuroimaging findings of 90 consecutive patients with acute ischemic stroke were evaluated.Results: The mean age of participants was 69.28 \u00b1 10 and 39 patients were female. The increased level of S100B and the decreased levels of sTRAIL with adropin were significantly associated with moderate to severe neurologic presentation (p=0.0001, p=0.002, p=0.002, respectively). On the control CT, a large infarct core was significantly associated with decreased serum levels of sTRAIL and adropin (p=0.001 and p=0.000, respectively); however, the levels of S100B were not significantly associated with good ASPECTS score (p=0.684). Disability and an unfavorable outcome were significantly related to the decreased level of sTRAIL and adropin (p=0.001 and p=0.000 for THRIVE score&gt;5, respectively). Decreased sTRAIL and adropin levels and an increased S100B level were correlated with the presence of large artery atherosclerotic etiologic factors (p=0.000, p=0.000, p=0.036, respectively).Conclusion: TRAIL and adropin serum levels were associated with poor clinical outcomes and greater infarcted area in acute ischemic stroke patients.<\/jats:p>","DOI":"10.7705\/biomedica.5943","type":"journal-article","created":{"date-parts":[[2022,7,13]],"date-time":"2022-07-13T15:21:02Z","timestamp":1657725662000},"page":"55-63","update-policy":"https:\/\/doi.org\/10.7705\/crossmark","source":"Crossref","is-referenced-by-count":10,"title":["The effectiveness of serum S100B, TRAIL, and adropin levels in predicting clinical outcome, final infarct core, and stroke subtypes of acute ischemic stroke patients"],"prefix":"10.7705","volume":"42","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6943-9586","authenticated-orcid":false,"given":"Ozge","family":"Altintas Kadirhan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0293-618X","authenticated-orcid":false,"given":"Okkes Taha","family":"Kucukdagli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7675-0014","authenticated-orcid":false,"given":"Bedia","family":"Gulen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"4444","published-online":{"date-parts":[[2022,5,1]]},"reference":[{"key":"108486","doi-asserted-by":"crossref","unstructured":"Goldstein LB, Bushnell CD, Adams RJ, Appel LJ, Braun LT, Chaturvedi S, et al. Guidelines for the primary prevention of stroke: A statement for healthcare professionals from the American Heart Association\/American Stroke Association. Stroke. 2014;42:517-84. https:\/\/doi.org\/10.1161\/STR.0000000000000046","DOI":"10.1161\/STR.0b013e3181fcb238"},{"key":"108487","doi-asserted-by":"crossref","unstructured":"Powers WJ, Derdeyn CP, Biller J, Coffey CS, Hoh BL, Jauch EC, et al. 2015 American Heart Association\/American Stroke association focused update of the 2013 guidelines for the early management of patients with acute \u0131schemic stroke regarding endovascular treatment. Stroke. 2015;46:3020-35. https:\/\/doi.org\/10.1161\/STR.0000000000000074","DOI":"10.1161\/STR.0000000000000074"},{"key":"108488","doi-asserted-by":"crossref","unstructured":"Campbell BCV, De Silva DA, Macleod MR, Coutts SB, Schwamm LH, Davis SM, et al. Ischaemic stroke. Nat Rev Dis Primers. 2019;5:70. https:\/\/doi.org\/10.1038\/s41572-019-0118-8","DOI":"10.1038\/s41572-019-0118-8"},{"key":"108489","doi-asserted-by":"crossref","unstructured":"Hewitt J, Castilla-Guerra L, Fern\u00e1ndez-Moreno M del C, Sierra C. Diabetes and stroke prevention: A review. Stroke Res Treat. 2012;673187. https:\/\/doi.org\/10.1155\/2012\/673187","DOI":"10.1155\/2012\/673187"},{"key":"108490","doi-asserted-by":"crossref","unstructured":"Prakash R, Li W, Qu Z, Johnson MA, Fagan SC, Ergul A. Vascularization pattern after ischemic stroke is different in control versus diabetic rats: Relevance to stroke recovery. Stroke. 2013;44:2875-82. https:\/\/doi.org\/10.1161\/STROKEAHA.113.001660","DOI":"10.1161\/STROKEAHA.113.001660"},{"key":"108491","doi-asserted-by":"crossref","unstructured":"Verma S, Buchanan MR, Anderson TJ. Endothelial function testing as a biomarker of vascular disease. Circulation. 2003;108:2054-9. https:\/\/doi.org\/10.1161\/01.CIR.0000089191.72957.ED","DOI":"10.1161\/01.CIR.0000089191.72957.ED"},{"key":"108492","doi-asserted-by":"crossref","unstructured":"Tisato V, Gonelli A, Voltan R, Secchiero P, Zauli G. Clinical perspectives of TRAIL: Insights into central nervous system disorders. Cell Mol Life Sci. 2016;73:2017-27. https:\/\/doi.org\/10.1007\/s00018-016-2164-7","DOI":"10.1007\/s00018-016-2164-7"},{"key":"108493","doi-asserted-by":"crossref","unstructured":"Secchiero P, Zauli G. TRAIL, a new weapon against neointimal hyperplasia. Cardiology. 2012;123:94-6. https:\/\/doi.org\/10.1159\/000342983","DOI":"10.1159\/000342983"},{"key":"108494","doi-asserted-by":"crossref","unstructured":"Marczuk N, Cecerska-Hery\u0107 E, Jesionowska A, Do\u0142\u0119gowska B. Adropin - physiological and pathophysiological role. Postepy Hig Med Dosw (Online). 2016;70:981-8. https:\/\/doi.org\/10.5604\/17322693.1220082","DOI":"10.5604\/17322693.1220082"},{"key":"108495","doi-asserted-by":"crossref","unstructured":"Wu L, Fang J, Chen L, Zhao Z, Luo Y, Lin C, et al. Low serum adropin is associated with coronary atherosclerosis in type 2 diabetic and non-diabetic patients. Clin Chem Lab Med. 2013;52:751-8. https:\/\/doi.org\/10.1515\/cclm-2013-0844","DOI":"10.1515\/cclm-2013-0844"},{"key":"108496","unstructured":"Weglewski A, Ryglewicz D, Mular A, Jury\u0144czyk J. Changes of protein S100B serum concentration during ischemic and hemorrhagic stroke in relation to the volume of stroke lesion. Neurologia i Neurochirurgia Polska. 2005;39:310-7."},{"key":"108497","doi-asserted-by":"crossref","unstructured":"Barber PA, Demchuk AM, Zhang J, Buchan AM. Validity and reliability of a quantitative computed tomography score in predicting outcome of hyperacute stroke before thrombolytic therapy. Lancet. 2000;355:1670-4. https:\/\/doi.org\/10.1016\/s0140-6736(00)02237-6","DOI":"10.1016\/S0140-6736(00)02237-6"},{"key":"108498","doi-asserted-by":"crossref","unstructured":"Goyal M, Demchuk AM, Menon BK, Eesa M, Rempel JL, Thornton J, et al. Randomized assessment of rapid endovascular treatment of ischemic stroke. N Engl J Med. 2015;372:1019-30. https:\/\/doi.org\/10.1056\/NEJMoa1414905","DOI":"10.1056\/NEJMoa1414905"},{"key":"108499","doi-asserted-by":"crossref","unstructured":"Adams HP Jr, Bendixen BH, Kappelle LJ, Biller J, Love BB, Gordon DL, et al. Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in Acute Stroke Treatment. Stroke. 1993;24:35-41. https:\/\/doi.org\/10.1161\/01.str.24.1.35","DOI":"10.1161\/01.STR.24.1.35"},{"key":"108500","doi-asserted-by":"crossref","unstructured":"Flint AC, Cullen SP, Rao VA, Faigeles BS, Pereira VM, Levy EI, et al. The THRIVE score strongly predicts outcomes in patients treated with the Solitaire device in the SWIFT and STAR trials. Int J Stroke. 2014;9:698-704. https:\/\/doi.org\/10.1111\/ijs.12292","DOI":"10.1111\/ijs.12292"},{"key":"108501","doi-asserted-by":"crossref","unstructured":"Aydin S. Three new players in energy regulation: Preptin, adropin and irisin. Peptides. 2014;56:94-110. https:\/\/doi.org\/10.1016\/j.peptides.2014.03.021","DOI":"10.1016\/j.peptides.2014.03.021"},{"key":"108502","doi-asserted-by":"crossref","unstructured":"Dassan P, Keir G, Brown M. Criteria for a clinically informative serum biomarker in acute ischaemic stroke: A review of S100B. Cerebrovasc Dis. 2009;27:295-302. https:\/\/doi.org\/ 10.1159\/000199468","DOI":"10.1159\/000199468"},{"key":"108503","doi-asserted-by":"crossref","unstructured":"Wunderlich MT, Wallesch CW, Goertler M. Release of neurobiochemical markers of brain damage is related to the neurovascular status on admission and the site of arterial occlusion in acute ischemic stroke. J Neurol Sci. 2004;227:49-53. https:\/\/doi.org\/10.1016\/j.jns.2004.08.005","DOI":"10.1016\/j.jns.2004.08.005"},{"key":"108504","doi-asserted-by":"crossref","unstructured":"Park SY, Kim MH, Kim OJ, Ahn HJ, Song JY, Jeong, JY, et al. Plasma heart-type fatty acid binding protein level in acute ischemic stroke: Comparative analysis with plasma S100B level for diagnosis of stroke and prediction of long-term clinical outcome. Clin Neurol Neurosurg. 2013;115:405-10. https:\/\/doi.org\/10.1016\/j.clineuro.2012.06.004","DOI":"10.1016\/j.clineuro.2012.06.004"},{"key":"108505","doi-asserted-by":"crossref","unstructured":"Watt V, Chamberlain J, Steiner T, Francis S, Crossman D. TRAIL attenuates the development of atherosclerosis in apolipoprotein E deficient mice. Atherosclerosis. 2011;215:348-54. https:\/\/doi.org\/10.1016\/j.atherosclerosis.2011.01.010","DOI":"10.1016\/j.atherosclerosis.2011.01.010"},{"key":"108506","doi-asserted-by":"crossref","unstructured":"Tufekci KU, Vurgun U, Yigitaslan O, Keskinoglu P, Yaka E, Kutluk K, et al. Follow-up analysis of serum TNF-related apoptosis-inducing ligand protein and mRNA expression in peripheral blood mononuclear cells from patients with ischemic stroke. Front Neurol. 2018;9:102. https:\/\/doi.org\/10.3389\/fneur.2018.00102","DOI":"10.3389\/fneur.2018.00102"},{"key":"108507","doi-asserted-by":"crossref","unstructured":"Kang YH, Park MG, Noh KH, Park HR, Lee HW, Son SM, et al. Low serum TNF-related apoptosis-inducing ligand (TRAIL) levels are associated with acute ischemic stroke severity. Atherosclerosis. 2015;240:228-33. https:\/\/doi.org\/ 10.1016\/j.atherosclerosis.2015.03.028","DOI":"10.1016\/j.atherosclerosis.2015.03.028"},{"key":"108508","doi-asserted-by":"crossref","unstructured":"Wu L, Fang J, Chen L, Zhao Z, Luo Y, Lin C, et al. Low serum adropin is associated with coronary atherosclerosis in type 2 diabetic and non-diabetic patients. Clin Chem Lab Med. 2014;52:751-8. https:\/\/doi.org\/ 10.1515\/cclm-2013-0844","DOI":"10.1515\/cclm-2013-0844"},{"key":"108509","doi-asserted-by":"crossref","unstructured":"Sato K, Yamashita T, Shirai R, Shibata K, Okano T, Yamaguchi M, et al. Adropin contributes to anti-atherosclerosis by suppressing monocyte-endothelial cell adhesion and smooth muscle cell proliferation. Int J Mol Sci. 2018;19:1293. https:\/\/doi.org\/10.3390\/ijms19051293","DOI":"10.3390\/ijms19051293"},{"key":"108510","doi-asserted-by":"crossref","unstructured":"Li L, Xie W, Zheng XL, Yin WD, Tang CK. A novel peptide adropin in cardiovascular diseases. Clin Chim Acta. 2016;453:107-13. https:\/\/doi.org\/10.1016\/j.cca.2015.12.010","DOI":"10.1016\/j.cca.2015.12.010"},{"key":"108511","doi-asserted-by":"crossref","unstructured":"Celik A, Balin M, Kobat K, Erdem MA, Baydas A, Bulut M, et al. Deficiency of a new protein associated with cardiac syndrome X, called adropin. Cardiovasc Ther. 2013;31:174-8. https:\/\/doi.org\/ 10.1111\/1755-5922.12025","DOI":"10.1111\/1755-5922.12025"},{"key":"108512","doi-asserted-by":"crossref","unstructured":"Altamimi TR, Gao S, Karwi QG, Fukushima A, Rawat S, Wagg CS, et al. Adropin regulates cardiac energy metabolism and improves cardiac function and efficiency. Metabolism. 2019;98:37-48. https:\/\/doi.org\/10.1016\/j.metabol.2019.06.005","DOI":"10.1016\/j.metabol.2019.06.005"},{"key":"108513","doi-asserted-by":"crossref","unstructured":"Secchiero P, Corallini F, Ceconi C, Parrinello G, Volpato S, Ferrari R, et al. Potential prognostic significance of decreased serum levels of TRAIL after acute myocardial infarction. PLoS ONE. 2009;4:e4442. https:\/\/doi.org\/10.1371\/journal.pone.0004442","DOI":"10.1371\/journal.pone.0004442"},{"key":"108514","doi-asserted-by":"crossref","unstructured":"Cartland SP, Genner SW, Mart\u00ednez GJ, Robertson S, Kockx M, Lin RC, et al. TRAILexpressing monocyte\/macrophages are critical for reducing inflammation and atherosclerosis. iScience. 2019;12:41-52. https:\/\/doi.org\/10.1016\/j.isci.2018.12.037","DOI":"10.1016\/j.isci.2018.12.037"},{"key":"108515","doi-asserted-by":"crossref","unstructured":"Butler AA, St-Onge MP, Siebert EA, Medici V, Stanhope KL, Havel PJ. Differential responses of plasma adropin concentrations to dietary glucose or fructose consumption in humans. Sci Rep. 2015;5:14691. https:\/\/doi.org\/10.1038\/srep14691","DOI":"10.1038\/srep14691"}],"container-title":["Biom\u00e9dica"],"original-title":[],"link":[{"URL":"https:\/\/revistabiomedica.org\/index.php\/biomedica\/article\/download\/5943\/4931","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/revistabiomedica.org\/index.php\/biomedica\/article\/download\/5943\/4931","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,11]],"date-time":"2022-08-11T21:10:36Z","timestamp":1660252236000},"score":1,"resource":{"primary":{"URL":"https:\/\/revistabiomedica.org\/index.php\/biomedica\/article\/view\/5943"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,1]]},"references-count":30,"journal-issue":{"issue":"Sp. 1","published-online":{"date-parts":[[2022,5,1]]}},"URL":"https:\/\/doi.org\/10.7705\/biomedica.5943","relation":{},"ISSN":["2590-7379","0120-4157"],"issn-type":[{"value":"2590-7379","type":"electronic"},{"value":"0120-4157","type":"print"}],"subject":[],"published":{"date-parts":[[2022,5,1]]},"assertion":[{"value":"2022-05-01","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}},{"value":"Yes","order":0,"name":"peer_reviewed","label":"Peer Reviewed","group":{"name":"peer_review","label":"Peer Review"}},{"value":"Instituto Nacional de Salud","name":"publisher","label":"This article is maintained by"},{"value":"Biomedica","name":"journaltitle","label":"Journal Title"},{"value":"Art\u00edculos originales","name":"content_type","label":"Content Type"}]}}